Genetic Technologies Operating Income

Genetic Technologies posts a operating income of $-19M as of June 2024. That compares with $-15M in the prior-year period — down 30.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Genetic Technologies's operating income was $-15M. The latest reading is $-19M — a 30.0% year-over-year decrease (period ending June 2024). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Genetic Technologies's financial statement story. At $-19M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GENE's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Genetic Technologies's other metric pages and overview cover the third.

Judging Genetic Technologies against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-19M here, then scan peer and history charts to see if the gap is persistent.